Gonorrhea is caused due to the infection of the bacterium Neisseria gonorrhea which usually affects the moist and warm areas of the body such as the vagina, anus, urethra, throat, and eyes. It is classified as the second most occurring sexually transmitted disease (STD) as it has the risk to spread through unprotected sex or having multiple sex partners. The high morbidity rate and eminent threat of gonorrhea being resistant to cephalosporin make it necessary to understand the disease epidemiology of gonorrhea. As per the latest research citing the Centers for Disease Control and Prevention’s 2016 report, the global prevalence of gonorrhea is 142.1 cases per 100,000 people. The occurrence is high in women in comparison to men and widely prevalent in regions such as North America, Latin America, Africa, and other developing nations of South Asia.
The World Health Organization has postulated a treatment guideline for gonorrhea to overcome the problem of microbial resistance, which consists of the use of antibiotics such as third-generation cephalosporins, doxycycline, azithromycin, gemifloxacin, etc. For effective diagnosis of gonorrhea, the cell culture standard test is considered as gold standard due to inherent features such as high specificity, high sensitivity, and relatively low cost. The problem associated with the cell culture of Neisseria is the need to maintain bacterial viability during storage and transport, and approximately 24-72 hours are required before a preliminary culture test result is obtained. The nucleic acid amplification test (NAAT) has been approved by the USFDA for analyzing genital specimens only and has been beneficial to gain positive results with very less genetic material, urine samples, and vaginal swabs. For analyzing extra genital specimens, gonorrhea diagnosis is performed with serological tests, monoclonal antibodies tests, and flow cytometry, etc.
Key players identified for the gonorrhea diagnostics market include:
Abbott Laboratories, Agilent Technologies, Beckman Coulter, Inc., Becton Dickinson & Company, bioMerieux, Inc., Cepheid, Inc., F. Hoffmann-La Roche AG, Ortho Clinical Diagnostics, PerkinElmer, Inc., Pfizer, Inc., Roche Diagnostics, Siemens AG, Tosoh Corporation and Others notable players.
Historical & Forecast Period
This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Gonorrhea Diagnostics market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
| ATTRIBUTE | DETAILS |
|---|---|
| Research Period | 2022-2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Year | 2022 |
| Unit | USD Million |
| Segmentation | |
Type
| |
|
Region Segment (2022-2032; US$ Million)
|
Key questions answered in this report
